Company Analysis
Sign in

Oculis Holding AG (OCS)

Nasdaq: OCS · Pharmaceutical Preparations · Zug, CH · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.1
◀ Past 4.7● Present 5.3▶ Future 5.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-CHF 99.0M-15.4%
Earnings per shareCHF -1.89+10.8%
Operating cash flow-CHF 66.3M-35.5%
CashCHF 81.3M+193.5%
Debtn/a
Shareholders’ equityCHF 196M+167.2%
Shares, diluted52.2M+29.3%
Return on equity-50.5%
The recordfrom its filings
Filings in 202618
Newest filingNov 3 · 424B5
Annual reportMar 4, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted14
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in CHF. Nothing here is a forecast.

News

Nov 3, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton OCS · research, not advice